For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 17,487 | 22,211* | 22,853 | 28,424 |
| General and administrative | 4,083 | 9,387* | 5,099 | 3,968 |
| Total operating expenses | 21,570 | 31,597 | 27,952 | 32,392 |
| Loss from operations | -21,570 | -31,597* | -27,952 | -32,392 |
| Interest income | 1,342 | 1,922* | 1,172 | 1,398 |
| Interest expense | 23 | 18* | 12 | 0 |
| Other expense, net | 7 | 1* | -64 | -223 |
| Loss before income tax provision | -20,244 | -29,693* | -26,856 | -31,217 |
| Income tax provision | 0 | 0* | 0 | 0 |
| Segment net loss | -20,244 | -29,693* | -26,856 | -31,217 |
| Unrealized loss on treasury securities, net of tax | -139 | -11 | 97 | -32 |
| Total other comprehensive income | -139 | -11* | 97 | -32 |
| Comprehensive loss | -20,383 | -29,705 | -26,759 | -31,249 |
| Basic EPS | -1.88 | 0.184 | -0.29 | -0.34 |
| Diluted EPS | -1.88 | 0.184 | -0.29 | -0.34 |
| Basic Average Shares | 10,744,621 | -161,497,962 | 91,086,464 | 91,085,506 |
| Diluted Average Shares | 10,744,621 | -161,497,962 | 91,086,464 | 91,085,506 |
Adicet Bio, Inc. (ACET)
Adicet Bio, Inc. (ACET)